[1] Blei AT,Cordoba J. Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol,2001,96（7）:1986-1976.
[2] Ferenci P,Lockwood A,Mullen K,et al. Hepatic encephalopathy-definition,nomenclature,diagnosis,and quantificiation:final report of the working party at the 11th World Congresses of Gastroenterology,Vienna,1998. Hepatology,2002,35（3）:716-721.
[3] Dhiman RK,Saraswat VA,Sharma BK,et al. Minimal hepatic encephalopathy:consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol,2010,25（6）:1029-1041.
[4] Wang JY,Zhang NP,Chi BR,et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol,2013,19（30）:4984-4991.
[5] 中华医学会消化病学分会,中华医学会肝病学分会. 中国肝性脑病诊治共识意见（2013年,重庆）. 中华肝脏病杂志,2013,21（9）:641-651.
[6] Vilstrup H,Amodio P,Bajaj J,et al. Hepatic encephalopathy in chronic liver disease:2014 practice guideline by the American Association for the study of liver diseases and the European association for the study of the liver. Hepatology,2014,60（2）: 715-735.
[7] Gronbaek H,Johnsen SP,Jepsen P,et al. Liver cirrhosis,other liver diseases,and risk of hospitalization for intracerebral haemorrhage:a Danish population-based case-control study. BMC Gastroenterol,2008,8:16-21.
[8] Waghray A,Waghray N,Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol,2015,5（S1）: S75-S81.
[9] Weissenborn K. Diagnosis of minimal hepatic encephalopathy. J Clin Exp Hepatol,2015,5（S1）:S54-S59.
[10] Dhiman RK,Kurmi R,Thumburu KK,et al. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci,2010,55:2381-2390.
[11] Riggio O,Ridola L,Pasquale C,et al. A simplified psychometric evaluation for the diagnosis of minimal hepatic encephalopathy. Clin Gastroenterol Hepatol,2011,9（7）:613-616.
[12] Das S,Ali S M,Seward J,et al. The mind and liver test:a new approach to the diagnosis of minimal hepatic encephalopathy in resource-poor settings. Int J Hepatol,2014,2014:475021.
[13] Romero-Gomez M,Cordoba J,Jover R,et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology,2007,45（4）:879-885.
[14] Wu D,Wu S M,Lu J,et al. Rifaximin versus nonabsobable disaccharides for the treatment of hepatic encephalopathy:a meta-analysis. Gastroenterol Res Pract,2013,2013:236963.
[15] Jiang Q,Jiang X H,Zheng M H,et al. Rifaximin versus nonabsobale disaccharides in the management of hepatic encephalopathy:a meta-analysis. Eur J Gastroenterol Hepatol,2008,20（11）:1064-1070.
[16] Scott LJ. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes. Drugs,2014,74（18）: 21532-2160.
[17] Khokhar N,Qureshi MO,Ahmad S,et al. Comparison of once a day rifaximin to twice a day dosage in prevention of recurrence of hepatic encephalopathyin patients with chronic liver disease. J Gastroenterol Hepatol,2015,Apr 13. doi:10.1111/jgh.12970. [Epub ahead of print].
[18] Zhu GQ,Shi KQ,Huang S,et al. Systematic review with network meta-analysis:the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Phamacol Ther,2015,41（7）:624-635. |
